Bristol-Myers Squibb Co., has added warnings to the label for the antibiotic Tequin. The antibiotic is used to treat various infections, including pneumonia, bronchitis and kidney infections. Since the approval of Tequin in 1999, there have been cases of life-threatening events. The new labeling contains updated warnings reflecting information from continued reports of serious hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar). Also, the revised Tequin prescribing information includes a contraindication in diabetic patients due to the serious reports of hypoglycemia and hyperglycemia. Sheller, Ludwig and Badey is investigating claims of injury caused by Tequin.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.